New Features in the Treatment of Androgen-Independent Prostate Cancer

E-ISSN： 1873-4286|10|5|513-522

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.10, Iss.5, 2004-02, pp. : 513-522

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

New Compounds Targeting the Androgen Receptor for Treatment of Advanced Prostate Cancer

Current Drug Targets, Vol. 17, Iss. 3, 2016-03 ,pp. : 290-302

Bentham Science Publishers

Access to resources Recommend Favorite

Resveratrol Antagonizes EGFR-Dependent Erk1/2 Activation in Human Androgen-Independent Prostate Cancer Cells with Associated Isozyme-Selective PKCα Inhibition

By Stewart Jubilee R. O'Brian Catherine A.

Investigational New Drugs, Vol. 22, Iss. 2, 2004-04 ,pp. : 107-117

Springer Publishing Company

Access to resources Recommend Favorite

Synthesis and cytotoxic activities of some 2-Arylnaphtho[2,3- d ]oxazole-4,9-dione derivatives on androgen-dependent (LNCaP) and androgen-independent (PC3) human prostate cancer cell lines

By Brandy Yakini

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1709-1714

Springer Publishing Company

Access to resources Recommend Favorite

Emerging targets in the AKT pathway for treatment of androgen-independent prostatic adenocarcinoma

By Graff Jeremy R

Expert Opinion on Therapeutic Targets, Vol. 6, Iss. 1, 2002-02 ,pp. : 103-113

Informa Healthcare

Access to resources Recommend Favorite

Androgen Receptor Antagonists in the Treatment of Prostate Cancer

Clinical Immunology, Endocrine & Metabolic Drugs, Vol. 1, Iss. 1, 2014-06 ,pp. : 11-19

Bentham Science Publishers

Access to resources Recommend Favorite